Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

Join Amber Hudgins, a pharmacist at Novant Health in Winston Salem, North Carolina, as she dives into an abstract from ACR 2022. In this video, she explores the differences between IL-23 inhibitors, Guselkumab (Gus) and Risankizumab (Riz), and their therapeutic profiles for psoriatic disease. She compares how these drugs target specific interleukins and examines their binding and functional characteristics. Discover fascinating insights and potential therapeutic benefits within this drug class.